Orexa is S1 Biopharma’s first therapy for HSDD in men. This indication represents a large, unmet need in that there are an estimated 16 million men with this diagnosis in the U.S. and Western Europe. Like women, men can receive benefits in the areas of desire, arousal and overall sexual satisfaction, with additional benefits appearing likely for the common problems of sexual performance anxiety and treatment-resistant erectile dysfunction.